Effect of extracorporeal shock wave combined with pregabalin on patients with post-herpetic neuralgia

Medicine (Baltimore). 2023 Jul 28;102(30):e34361. doi: 10.1097/MD.0000000000034361.

Abstract

Post-herpetic neuralgia (PHN) is a chronic pain that is difficult to treat and lasts a long time, which poses a threat to patients' physical and mental health (MH) and quality of life. To analyze the effectiveness of extracorporeal shock wave (ESW) combined with pregabalin on PHN and its impact on PHN patients' quality of life with the help of a random number table. Totally 164 PHN patients were assigned to a control group (n = 82) or an observation group (n = 82). The observation group was given pregabalin combined with ESW treatment, while the control group was only given pregabalin. In the 2 groups, the general clinical data of the patients were compared. The inflammation levels including erythrocyte sedimentation rate (ESR), CRP, lymphocyte count and albumin level in both groups were compared prior to and following therapy. In addition, the difference between pretreatment and post-treatment in the 2 groups was compared with respect to neuralgia and quality of life. After treatment, the observation group exhibited much lower ESR and CRP but quite higher lymphocyte count and albumin level relative to the control group (P < .05). Additionally, the improvement in visual analogue scale (VAS) scores and short form 36 (SF-36) scale scores including role-emotional (RE), MH, physical function (PF), general health (GH), bodily pain (BP), social function (SF), vitality (VT), and role-physical (RP) scores in the 2 groups were pronounced following treatment, which was more apparent in the observation group (P < .05). The combination of ESW with pregabalin can reduce the inflammation, improve the quality of life of PHN patients and effectively relieve their neuralgia.

MeSH terms

  • Albumins / therapeutic use
  • Analgesics / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Neuralgia* / drug therapy
  • Neuralgia, Postherpetic* / drug therapy
  • Pregabalin / therapeutic use
  • Quality of Life
  • Treatment Outcome

Substances

  • Pregabalin
  • Albumins
  • Analgesics